

Special Issue

Etiology, Clinical Presentation, Antibiotic and Surgical Treatment of Infective Endocarditis

Message from the Guest Editors

Infective endocarditis (IE) is a harmful disease with a recently increasing incidence. Patients around the fifth or sixth decade of life are the ones mainly affected, but the percentage of elderly patients is increasing. Moreover, IE is one of the most severe complications in intravenous drug abusers (IVDAs), who are often young. *Staphylococcus aureus* is the most frequent and worrying pathogen, but enterococci is emerging in those with increasing age. New early diagnostic methods, such as PET or CT, and new technologies to detect and identify bacteria using PCR amplification and sequencing, are attracting attention. As for treatment, medical therapy alone is often not enough and surgery is frequently required. Surgical treatment may be quite challenging, and in-hospital mortality associated with IE remains high, sometimes exceeding 20%. With this Special Issue, we encourage submissions of studies, including new perspectives on the etiology, clinical presentation, and treatment modalities of IE, a disease whose outcome appears definitely improvable.

Guest Editors

Prof. Dr. Francesco Santini
Prof. Dr. Francesco Onorati
Dr. Antonio Salsano

Deadline for manuscript submissions

closed (31 October 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/191240

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)